Practical Management of Oligometastatic Non-Small-Cell Lung Cancer.
Katie JasperBrendon M StilesFiona McDonaldDavid A PalmaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Local ablative therapies, including surgery or stereotactic radiotherapy (SABR), are becoming an integral component in the treatment of oligometastatic disease in non-small-cell lung cancer. In this review, we summarize recent randomized evidence supporting progression-free survival and overall survival benefits of local ablation in these patients, as well as upcoming phase III data which should help us better understand the ideal treatment conditions and provide more insight into the oligometastatic state. Since practical management of oligometastatic disease in non-small-cell lung cancer can be challenging, we discuss a modern framework to identify patient, tumor, and treatment characteristics that can best guide management.
Keyphrases
- phase iii
- free survival
- open label
- clinical trial
- double blind
- newly diagnosed
- minimally invasive
- radiation therapy
- combination therapy
- squamous cell carcinoma
- randomized controlled trial
- case report
- placebo controlled
- small cell lung cancer
- prognostic factors
- locally advanced
- electronic health record
- big data
- radiofrequency ablation
- smoking cessation
- data analysis